Results 191 to 200 of about 146,499 (323)

Dissecting the Cell-killing Mechanism of the Topoisomerase II-targeting Drug ICRF-193 [PDF]

, 2004
Vibe H. Oestergaard, Birgitta R. Knudsen, Anni H. Andersen   +2 more
openalex   +1 more source

Hemophagocytic Lymphohystiocytosis in a Patient With Suspected Acute Myeloid Leukemia and Recent Viral Illness Compatible With Dengue: A Case Report and Literature Review

Cancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background Hemophagocytic lymphohistiocytosis, or HLH, is a very rare and aggressive disorder of the immune system, for which the trigger may be an infection, malignancy, or autoimmune disease. It has predominantly been described as triggered by T/NK lymphomas, but acute myeloid leukemia‐induced HLH is a very rare occurrence.
Halima Saleh, Sariya Khan, Huda Albraim, Sahar Albraim, Amatul Rafey, Mable Pereira, Tarek Mohammed   +6 more
wiley   +1 more source

Coumarin-Augmented Thiazole Hybrids as Dual Anticancer and Antibacterial Agents. [PDF]

Chem Biol Drug Des
Matar IK, Zaki MEA, Muhammad ZA, Awwad DA, Al-Hussain SA, Matta CF, Kassab RM.   +6 more
europepmc   +1 more source

Molecular and cellular effects of the combined treatment with Camptothecin and Roscovitine in human lung and colon adenocarcinoma cells [PDF]

, 2008
De Mattia, Roberta
core   +1 more source

A Strategy for Identifying Novel, Mechanistically Unique Inhibitors of Topoisomerase I

, 1992
Sidney M. Hecht, David E. Berry, Laurie MacKenzie, Robert Busby, Christopher A. Nasuti   +4 more
openalex   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Enzyme-DNA Interactions Affect the Catalytic Inhibition of Mycobacterial Gyrases by Antibacterial Drugs. [PDF]

ACS Infect Dis
Armenia JF, Osheroff N.
europepmc   +1 more source

DNA topoisomerase III from extremely thermophilic archaebacteria. ATP-independent type I topoisomerase from Desulfurococcus amylolyticus drives extensive unwinding of closed circular DNA at high temperature

, 1991
Alexeï Slesarev, D.A. Zaitzev, V. M. Kopylov, Karl O. Stetter, Sergei A. Kozyavkin   +4 more
openalex   +1 more source

Data from Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity

, 2023
Andrea Emanuelli, Aurora P. Borroni, Liat Apel‐Sarid, Pooja A. Shah, Dhanoop Manikoth Ayyathan, Praveen Koganti, Gal Levy‐Cohen, Michael B. Blank   +7 more
openalex   +1 more source

Antiplasmodial Activity and Pharmacokinetic Profiling of Cryptolepine and 2,7‐Dibromocryptolepine With a View to Informing the Design of Novel Antimalarial Cryptolepine Analogues

Drug Development Research, Volume 87, Issue 2, April 2026.
ABSTRACT The roots of the climbing shrub Cryptolepis sanguinolenta are traditionally used in West Africa for the treatment of malaria. The principal constituent, cryptolepine (1), has been shown to have antimalarial activity but there are concerns regarding its toxicity on account of its DNA‐intercalating property.
Elodie Chenu, James Duffy, Arnold Donkor Forkuo, Stephen Y. Gbedema, Seham Abdelall, Muhammad Wahajuddin, Huw S. Jones, Colin W. Wright   +7 more
wiley   +1 more source